China's antibiotic monopoly leaves Western nations dangerously exposed

China's antibiotic monopoly leaves Western nations dangerously exposed

Open book with Chinese text and intricate illustrations, believed to be the earliest known Chinese medical text.

China's antibiotic monopoly leaves Western nations dangerously exposed

A new report warns that China’s dominance over antibiotic production poses a serious risk to Western health security. By controlling key ingredients and suppressing prices, the country has pushed most manufacturing out of Europe and North America. The result is a fragile supply chain that leaves Britain, the US, and other nations vulnerable to shortages. China now supplies the vast majority of raw materials used in antibiotics. Britain depends on it for up to 90% of its ingredients, while India—another major producer—relies on China for 91.5% of its own supplies. Just four Chinese firms provide over half of India’s antibiotic imports, creating a heavy concentration of power.

The global penicillin supply chain is particularly exposed. With only seven Chinese factories producing the drug, any export restrictions or political decisions could cause severe disruptions. Europe’s capacity has shrunk to a single penicillin plant in Austria, leaving little backup if supplies falter. The report highlights the risks of sudden shortages in the UK and other Western countries. It urges governments to rebuild antibiotic production outside China and India. It also suggests including supply-chain security in Nato’s strategic planning to treat it as a national security issue.

Without action, Western nations remain at risk of drug shortages due to their reliance on Chinese production. The report calls for urgent investment in local manufacturing to reduce dependence. Strengthening supply chains is now seen as critical for both health and defence planning.

Neueste Nachrichten